Whether a child is fighting to refuse treatment or a terminally ill adult desperately wants to try an experimental drug, patients with cancer throughout the country are attempting to break barriers that keep them from making personal choices about their treatment.
What's New in Multiple Myeloma Therapy?
FDA NewsMultiple MyelomaNewsworthy
In the first 3 months of 2015, new developments in myeloma drugs could have important implications for the survival and quality of life of patients with multiple myeloma.
Common Vaccine Offers Hope Against Aggressive Brain Tumors
The median survival rate for patients with glioblastoma, an aggressive type of brain tumor, is approximately 14 months. Approximately 17% of all brain tumors are glioblastomas.
Lexicon Announces the Launch of
NewsworthyWeb Exclusives
The new site is aimed at providing education for people with carcinoid syndrome, caregivers, and medical providers.
Kisqali a New First-Line Treatment for Patients with Advanced Breast Cancer
FDA NewsNewsworthy
In March 2017, the FDA approved Kisqali (ribociclib), in combination with an aromatase inhibitor, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Keytruda Now Available for Patients with Relapsed Classical Hodgkin Lymphoma
FDA NewsNewsworthy
In March 2017, the FDA approved Keytruda (pembrolizumab), anti-PD-1 immunotherapy, for the treatment of patients with classical Hodgkin lymphoma who are not responding to other therapy or whose disease (relapsed) returned after 3 or more therapies. Keytruda was previously approved for several cancers.
Revlimid Approved for Maintenance Therapy in Patients with Multiple Myeloma After Transplant
FDA NewsNewsworthy
In February 2017, the FDA approved the oral drug Revlimid (lenalidomide) for maintenance (continuing) therapy for patients with multiple myeloma who had autologous hematopoietic stem-cell transplant. Revlimid was previously approved for multiple myeloma and for other types of cancer.
Imbruvica First Non-Chemotherapy Drug Approved for Patients with Marginal Zone Lymphoma
FDA NewsNewsworthy
In January 2017, the FDA approved Imbruvica (ibrutinib) for the treatment of patients with marginal zone lymphoma who need systemic therapy and have received at least 1 previous anti-CD20-based therapy.
Opdivo a New Treatment Option for Patients with Advanced or Metastatic Bladder Cancer
FDA NewsNewsworthy
In February 2017, the FDA approved Opdivo (nivolumab), anti-PD-1 immunotherapy, for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Rubraca a New Oral Treatment Approved for Patients with Advanced Ovarian Cancer
FDA NewsNewsworthy
In December 2016, the FDA approved Rubraca (rucaparib), a new oral PARP inhibitor, for the treatment of advanced ovarian cancer with a BRCA mutation (alteration) in patients who had received at least 2 chemotherapies.
Page 1 of 6
Results 1 - 10 of 55

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.